Recently, cardiovascular diseases (CVDs) were identified as the leading cause of mortality, imposing a heavy burden on health care systems and the social economy. Nicotinamide adenine dinucleotide (NAD⁺), as a pivotal co-substrate for a range of different enzymes, is involved in many signal transduction pathways activated in CVDs. Emerging evidence has shown that NAD⁺ can exert remediating effects on CVDs by regulating metabolism, maintaining redox homeostasis and modulating the immune response. In fact, NAD⁺ might delay ageing through sirtuin and non-sirtuin pathways and thus contribute to interventions for age-related diseases such as CVDs. Considering that robust clinical studies of NAD⁺ are ongoing, we discuss current challenges and the future translational potential of NAD⁺ based on existing studies and our understanding. Despite some remaining gaps in its clinical application, NAD⁺ has been shown to have broad prospects and pan-effects, making it a suitable prophylactic drug for CVDs.

最近，心血管疾病（CVDs）被确定为死亡的主要原因，给医疗保健系统和社会经济带来沉重负担。烟酰胺腺嘌呤二核苷酸 (NAD ⁺ ) 作为一系列不同酶的关键共底物，参与了 CVD 中激活的许多信号转导途径。新出现的证据表明，NAD ⁺可以通过调节新陈代谢、维持氧化还原稳态和调节免疫反应来对 CVD 发挥治疗作用。事实上，NAD ⁺可能通过 sirtuin 和非 sirtuin 途径延缓衰老，从而有助于干预与年龄相关的疾病，如 CVD。^{考虑到 NAD +}的稳健临床研究正在进行中，我们根据现有研究和我们的理解讨论当前的挑战和 NAD ^{+的未来转化潜力。}尽管在临床应用方面还存在一些空白，但 NAD ⁺已被证明具有广阔的前景和泛效应，使其成为适合心血管疾病的预防药物。